Skip to content
DataLookout
Menu

HI-PEITHONCT04790370

Ultrasound-facilitated, Catheter-directed, Thrombolysis in Intermediate-high Risk Pulmonary Embolism

StatusCompleted
PhasePhase 4
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

The 50 most recent of 61 versions: 34 with changes below, 16 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Results posted: Nov 16, 2026 Show 5 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 35 words
    • Trial completed
    • Study completion date changed from estimate of Aug 2026 to Aug 18, 2026
    • Publications: details revised at 26 of 29 entries
  2. Minor Study sites: 61 to 60v56
  3. Minor Study sites: 62 to 61v55
  4. Notable Eligibility criteria revised
    • Study sites: 63 to 62
    v54
  5. Minor Primary completion date changed from estimate of Aug 2025 to Jul 31, 2025v51
Show 29 earlier versionsHide 29 earlier versions
  1. Minor Trial status: Recruiting to Active, Not Recruiting
    • Study sites: 72 to 63
    v50
  2. Minor Site details revised at 7 of 72 sitesv47
  3. Minor Site details revised at 3 of 72 sitesv46
  4. Minor Site details revised at 1 of 72 sitesv45
  5. Minor Site details revised at 3 of 72 sitesv44
  6. Minor Site details revised at 1 of 72 sitesv43
  7. Minor Site details revised at 2 of 72 sitesv42
  8. Minor Site details revised at 4 of 72 sitesv41
  9. Minor Site details revised at 1 of 72 sitesv40
  10. Minor Site details revised at 1 of 72 sitesv39
  11. Minor Site details revised at 2 of 72 sitesv38
  12. Minor Study sites: 70 to 72v36
  13. Minor Study sites: 64 to 70v35
  14. Minor Study sites: 65 to 64v34
  15. Minor Site details revised at 2 of 65 sitesv33
  16. Notable Primary completion date: Jul 2024 to Aug 2025
    • Enrollment target: 406 to 544
    • Study completion date: Jul 2025 to Aug 2026
    v30
  17. Minor Site details revised at 1 of 65 sitesv26
  18. Minor Site details revised at 2 of 65 sitesv25
  19. Minor Site details revised at 2 of 65 sitesv23
  20. Minor Site details revised at 4 of 65 sitesv22
  21. Minor Site details revised at 4 of 65 sitesv20
  22. Minor Site details revised at 6 of 65 sitesv19
  23. Minor Study sites: 64 to 65v18
  24. Minor Site details revised at 4 of 64 sitesv17
  25. Minor Site details revised at 1 of 64 sitesv16
  26. Minor Study sites: 65 to 64v15
  27. Minor Study sites: 63 to 65v14
  28. Minor Study sites revised (63)v13
  29. Minor Study sites: 61 to 63v12
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants With PE-Related Mortality
Timeframe: Within seven days of randomization
Number of Participants With Recurrent Pulmonary Embolism
Timeframe: Within seven days of randomization
Number of Participants With Cardiorespiratory Decompensation or Collapse
Timeframe: Within seven days of randomization

Arms and interventions

AnticoagulationActive comparator

Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH)

Anticoagulation and EkoSonicTM Endovascular SystemActive comparator

Low-molecular weight heparin (LMWH) or unfractionated heparin (UFH) and EkoSonicTM Endovascular System \[ultrasound-facilitated catheter-directed delivery of thrombolytic: 2 mg bolus/catheter + 1 mg/hour/catheter for 7 hours (total of 9 or 18 mg\]

Drugs: Anticoagulation with heparin

Devices: EkoSonicTM Endovascular System

Sites

60 sites in 9 countries

United States 28, Germany 11, Austria 4, France 3, Netherlands 3, Poland 3, Switzerland 3, United Kingdom 3, Ireland 2